91大神

Skip to Content on 91大神.org
You're location is
All Regions
91大神r

Nationally Recognized Pediatric Care

Our hospitals are ranked by U.S. News & World Report as among the best in the nation in multi-specialties.

Find Out Why!
Closeup of a person holding a phone using the 91大神 app.

We Make Health Care Easy With 91大神 Children's MyChart

Access communications, appointment and symptom tracking and more.

Online Bill Pay

Paying a bill online is easy and secure.

Learn More

Send a Free E-Card

Brighten the day of your loved one staying at one of our hospitals.聽

Give It a Try
Young child posing with arms out like he is flying.

KidsHealth Library

Healthy living for聽parents, kids and聽teens.

Research
# #

    Russell Taylor Sundby, MD

    Hematology/Oncology
    (800) 416-4441

    Primary Office

    91大神 Children's Hospital, Delaware 91大神 Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803
    Appointment: (800) 416-4441

    Education & Training

    Fellowship

    • Pediatric Hematology-Oncology - National Institutes of Health, 2020
    • Pediatric Hematology-Oncology - Johns Hopkins University School of Medicine, 2020

    Residency

    • Pediatrics - University of California, San Francisco, 2017

    Medical/Dental School

    • MD - Vanderbilt University School of Medicine, 2014

    Board Certifications

    • American Board of Pediatrics/Pediatric Hematology-Oncology

    Insurance Accepted

    • Aetna HMO
    • Aetna PPO/POS/EPO
    • Amerihealth Caritas Delaware
    • Amerihealth Caritas Delaware VIP Next (DE - All Sites) (PA - Delaware & Chester County Sites & TJU Sites Only)
    • Carefirst MD Community Health Plan Mcaid
    • Cigna Lifesource Transplant
    • Cigna/Great West HMO EPO POS
    • Cigna/Great West PPO
    • Delaware Medicaid/Diamond State
    • First Health/Affordable PPO
    • Geisinger Health Plan Commercial
    • Highmark Blue Cross Blue Shield of Delaware
    • Highmark Medicaid Health Options
    • Independance Blue Cross/Amerihealth/Keystone Health Plan
    • Insurance Administrators of America
    • INTEGRA Administrative Group (ClaimsBridge)
    • Lifetrac Transplant
    • Maryland Medicaid
    • Multiplan PPO
    • National Transplant (Humana)
    • Olympus Managed Healthcare PPO DE/PA
    • Preferred Healthcare PPO
    • Priority Partners John Hopkins
    • Private Health Care Systems (PHCS)
    • Qualcare HMO/POS/PPO
    • Six Degrees Health Transplant
    • Six Degrees Health-Tribado
    • Star Healthcare Network
    • Three Rivers Provider Network
    • Tricare/Humana Military Health Services/CHAMPVA
    • UPMC Medicaid/CHIP
    • US Family Health Plan
    • Wellpoint Maryland Medcaid

    • Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials; Clinical Trials; (2024).

    • Supplementary Table S5 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Table S5 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Table S4 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Table S3 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Table S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Figure S2 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Unknown Source; (2024).

    • Supplementary Table S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Figure S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Brain Metastasis in Pediatric Patients with Osteosarcoma; Current Oncology; (2024).

    • Data from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Unknown Source; (2024).

    • Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Clinical Cancer Research; (2024).

    • Supplementary Figure S1 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Unknown Source; (2024).

    • Supplementary Figure S3 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Unknown Source; (2024).

    • Supplementary Figure S4 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Unknown Source; (2024).

    • Supplementary Tables S1-S3 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics; Unknown Source; (2024).

    • Data from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Data from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Dataset S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Dataset S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Figure S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Figure S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Figure S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Table S4 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Supplementary Table S3 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma; Unknown Source; (2024).

    • Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics; Unknown Source; (2024).

    • Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Clinical Cancer Research; (2023).

    • Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Data from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Unknown Source; (2023).

    • Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome.; JAMA dermatology; (2023).

    • Data from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Unknown Source; (2023).

    • Supplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Unknown Source; (2023).

    • Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Unknown Source; (2023).

    • Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Unknown Source; (2023).

    • Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Unknown Source; (2023).

    • Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma; Unknown Source; (2023).

    • MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors; Clinical Cancer Research; (2023).

    • Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients; npj Precision Oncology; (2023).

    • A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma; Clinical Cancer Research; (2023).

    • Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA; Cancer Discovery; (2023).

    • Liquid biopsies in pediatric oncology: opportunities and obstacles; Current Opinion in Pediatrics; (2021).

    • Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study; PLOS Medicine; (2021).

    • Transduction of Human CD34+ Cells with Recombinant TAT-NF-YA Protein Enhances Their Ex Vivo Expansion and Repopulating Potential in NOD/SCID Mice; Blood; (2008).

    • OC005: Ultrasound bioeffects: Quantification of cellular damage in animal fetal liver after use of Doppler pulse to measure ductus venosus; Ultrasound in Obstetrics and Gynecology; (2008).

    • English